Concert Completes THRIVE-AA2 Clinical Trial Evaluating CTP-543 in Alopecia Areata

August 1st, 2022

Concert Pharmaceuticals has reported positive results in the second of two Phase 3 trials, THRIVE-AA2, to evaluate the efficacy and safety of CTP‑543 in adult patients with moderate to severe alopecia areata.

These data, along with data from the first Phase 3 clinical trial, THRIVE-AA1, are intended to form the basis of a New Drug Application (NDA) planned to be submitted to the U.S. Food and Drug Administration (FDA) in the first half of 2023.

CTP-543, an oral selective inhibitor of Janus kinases JAK1 and JAK2, is in clinical development for the treatment of moderate to severe alopecia areata in adults. CTP-543 is an investigational drug and has not been approved by the FDA or any regulatory authority for any use.

Back to Top